|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 5/0784 | (2010.01) |
| C12N2506/11 | (2013.01) | ||
| C12N 5/24 | (2006.01) | ||
| C12N 5/064 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K2239/38 | (2023.05) | ||
| A61K 35/14 | (2015.01) | ||
| C12N 5/0639 | (2013.01) | ||
| A61K 40/19 | (2025.01) | ||
| A61K 40/24 | (2025.01) | ||
| A61K 40/42 | (2025.01) |
| (11) | Number of the document | 3317403 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16818706.0 |
| Date of filing the European patent application | 2016-06-29 | |
| (97) | Date of publication of the European application | 2018-05-09 |
| (45) | Date of publication and mention of the grant of the patent | 2025-03-05 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/040134 |
| Date | 2016-06-29 |
| (87) | Number | WO 2017/004230 |
| Date | 2017-01-05 |
| (30) | Number | Date | Country code |
| 201562187086 P | 2015-06-30 | US |
| (72) |
BOSCH, Marnix, L. , US
|
| (73) |
NorthWest Biotherapeutics, Inc. ,
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814,
US
|
| (54) | OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE |
| OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE |